Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.38 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.38 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964883 | 1.00 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL7532766 | 0.89 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL7536141 | 0.89 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL14090694 | 0.89 | CYP19A1 (0.45) | CYP19A1ACP1PTPN12PTPN13SSU72 | |
| SCHEMBL7618225 | 0.88 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL7527737 | 0.86 | POLB (0.43) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL7621987 | 0.86 | POLB (0.43) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL4629374 | 0.85 | ADRB3 (0.47) | L3MBTL1ALDH1A1 | |
| SCHEMBL27575302 | 0.84 | ADRB3 (0.43) | L3MBTL1ALDH1A1PTPN1PTPN2PTPN6 | |
| SCHEMBL7606232 | 0.83 | CYP19A1 (0.41) | CYP19A1ACP1PTPN12PTPN13SSU72 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2035004-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | Parion Sciences, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146869-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | L3MBTL1 3988/4885ALDH1A1 1434/4885PTPN1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.